Research, development, and manufacturing of innovative therapies for serious diseases using biotechnology.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: January 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Genethon
B
Research and development of gene therapy medicines for the treatment of rare diseases.
Takeda
B
Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
CSL
A
Development and provision of biotherapies for rare and serious diseases, including bleeding disorders, immunodeficiencies, and neurological disorders.
Initiatives identified among leaders
Amélioration de l'accès aux soins de santé
“CSL améliore l'accès aux soins de santé en fournis...” - CSLRéduction des déchets et des émissions de CO2
“Takeda réduit ses déchets et ses émissions de CO2” - TakedaDéfinition d'une politique de signalement des irrégularités
“CSL a mis en place une politique de signalement de...” - CSL60% of similar organizations communicate on CSR issues
+1886 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports